BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF ANNUAL GENERAL MEETING
The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed on a show of hands.
As set out in the circular to shareholders dated 4 June 2021, Resolutions 9 and 10, in connection with the appointment of the auditor, were withdrawn. The AGM was subsequently adjourned and will be reconvened on 24 June 2021 at 1:05 p.m. at the offices of Herbert Smith Freehills LLP, Exchange Hose, Primrose Street, London, EC2A 2EG following the conclusion of the General Meeting convened for the same day at 1.00 p.m. Resolution 1, in connection with the approval of the annual report and financial statements for the year ended 31 December 2020 will be proposed at the adjourned AGM.
The proxy votes received in relation to these resolutions were as follows:
| Resolutions
| Votes For
| % | Votes Against
| % | Votes at Chairman's Discretion | Votes Withheld |
| 1: To receive and accept the annual report and financial statements
| Adjourned
| |||||
| 2: To approve the Directors' Remuneration Report
| 613,712,139 | 99.99 | 15,334 | 0.01 | 0 | 669 |
| 3: To approve the Directors' Remuneration Policy
| 613,712,139 | 99.99 | 15,334 | 0.01 | 0 | 669 |
| 4: To re-elect Harry Hyman as a Director
| 613,728,142 | 100 | 0 | 0 | 0 | 0 |
| 5: To re-elect Colin Bond as a Director
| 613,728,142 | 100 | 0 | 0 | 0 | 0 |
| 6: To re-elect Duncan Budge as a Director
| 613,728,142 | 100 | 0 | 0 | 0 | 0 |
| 7: To re-elect Stephanie Léouzon as a Director
| 613,728,142 | 100 | 0 | 0 | 0 | 0 |
| 8: To elect Rolf Soderstrom as a Director
| 613,727,803 | 100 | 0 | 0 | 0 | 339 |
| 9: To appoint Ernst & Young LLP as Auditor to the Company
| Withdrawn | |||||
| 10: To authorise the Directors to determine the remuneration of the Auditor
| Withdrawn | |||||
| 11: To approve the Company's dividend payment policy
| 613,728,142 | 100 | 0 | 0 | 0 | 0 |
| 12: To authorise the Company to make market purchases of ordinary shares
| 613,728,142 | 100 | 0 | 0 | 0 | 0 |
| 13: To authorise the Company to hold general meetings on 14 clear days' notice
| 613,710,808 | 99.99 | 17,334 | 0.01 | 0 | 0 |
A copy of resolutions 12 and 13 has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
17 June 2021
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
